Arrowhead Pharma (ARWR)

$36.06 -0.88 (-2.38%)
Market Cap 5.11B
Revenue (ttm) 3.55M
Net Income (ttm) -599.49M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -16,887.04%
Debt to Equity Ratio 0.46
Volume 1,500,500
Avg Vol 2,554,246
Day's Range N/A - N/A
Shares Out 138.26M
Stochastic %K 48%
Beta 1.13
Analysts Strong Sell
Price Target $44.21

Company Profile

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's product pipeline includes Plozasiran, which has completed Phase 3 clinical trial to treat hypertriglyceridemia, dyslipidemia, and familial chylomicronemia syndrome; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; and Fazirsiran that is in Phase 3 clinical trial for the treatment of liver disease associated with alpha-1 antitryp...

Industry: Biotechnology
Sector: Healthcare
Phone: 626 304 3400
Fax: 626 304 3401
Address:
177 East Colorado Boulevard, Suite 700, Pasadena, United States
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 10 at 2:50 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $ARWR Current Share Price: $36.94 Contracts: $ARWR January 15, 2027 $40 Calls Scale in: $8.61- $10.53 Scale out: $13.40-$17.23 Can Easily Capture: 60% ROI Blended DTE: 463 Days | Join Elites here: https://liquidtheta.com/
0 · Reply
Steppinstone
Steppinstone Oct. 9 at 9:49 PM
$ARWR Interesting that an analyst covering IONS recently noted that Tryngolza would generate $ 1 billion in annual peak sales. That bodes very favorably for ARWR’s Plozasiran which is best in class and the superior drug. Been following ARWR for over a decade so it will be satisfying to see approval of its first drug in the coming weeks.
2 · Reply
skeezbag
skeezbag Oct. 9 at 7:04 PM
$ARWR don't go past 36.12 because that would make the picture painters gap not real!
0 · Reply
skeezbag
skeezbag Oct. 9 at 3:06 PM
$ARWR get ready to rage sheep
1 · Reply
Investor12341234
Investor12341234 Oct. 9 at 10:40 AM
$ARWR I wonder, how come the IV of NOV options are just average and not very high due to the FDA decision expected?
1 · Reply
Drashkawisha
Drashkawisha Oct. 9 at 5:20 AM
$ARWR The Final 3-Point Case for Arrowhead ($ARWR): FINANCIAL FORTRESS: The company holds over $900 Million in cash with a projected runway extending into 2028. This adheres perfectly to the "Zero Dilution Risk" rule, making it one of the safest setups in biotech. CLINICAL SUPERIORITY: The core drug (Plozasiran) is an RNAi therapeutic that demonstrated 80% triglyceride reduction and offers quarterly dosing for FCS, which is a significant competitive edge over monthly treatments. IMMINENT CATALYST: The PDUFA is confirmed for November 18, 2025. The current stock price (~$36.54) is a rare deep discount on the consensus analyst target (up to $80), making this a prime "Add-to-Position" opportunity.
1 · Reply
Food4Thought
Food4Thought Oct. 8 at 11:02 PM
$ARWR Someone who just reported on Oct 7th, loaded up very nicely. Nice increase of their position by 1,388% (over 380K shares valued over $13 million). You think they might have done some homework prior to this size of an increase?
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 8 at 6:18 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $ARWR Current Share Price: $36.85 Contracts: $ARWR January 15, 2027 $40 Calls Scale in: $8.67- $10.60 Scale out: $13.49-$17.34 Can Easily Capture: 60% ROI Blended DTE: 465 Days | Join Elites here: https://liquidtheta.com/
0 · Reply
skeezbag
skeezbag Oct. 8 at 1:53 PM
$ARWR almost time to rage against the GAP clowns
0 · Reply
TheSteveSmiths1
TheSteveSmiths1 Oct. 8 at 1:21 PM
$ARWR the numbers on this drug get insane quickly if you assume a 10k a year pricepoint. The true crown jewel. 1mill customer = $10 billion per year 5mill = $50 Billion per year 10mill = $100 billion per year
0 · Reply
Latest News on ARWR
Arrowhead Pharmaceuticals Files CTA for Investigational ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

Oct 7, 2025, 7:30 AM EDT - 2 days ago

Arrowhead Pharmaceuticals Files CTA for Investigational ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals

Sep 29, 2025, 7:11 AM EDT - 10 days ago

4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals

ASMB ATRA CORT

Arrowhead Pharmaceuticals Files Complaint for Declaratory Judgment Against Ionis Pharmaceuticals

Sep 11, 2025, 7:30 AM EDT - 4 weeks ago

Arrowhead Pharmaceuticals Files Complaint for Declaratory Judgment Against Ionis Pharmaceuticals

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 10, 2025, 2:55 PM EDT - 4 weeks ago

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies

Sep 10, 2025, 7:30 AM EDT - 4 weeks ago

Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript

Sep 9, 2025, 1:42 PM EDT - 4 weeks ago

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents At Cantor Global Healthcare Conference 2025 Transcript

Sep 7, 2025, 9:35 PM EDT - 4 weeks ago

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents At Cantor Global Healthcare Conference 2025 Transcript

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents At Citi's 2025 Biopharma Back To School Conference (Transcript)

Sep 3, 2025, 4:00 PM EDT - 5 weeks ago

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents At Citi's 2025 Biopharma Back To School Conference (Transcript)

Arrowhead: Upcoming Plozasiran PDUFA Review Date And Subsequent Expansion In Place

Sep 3, 2025, 1:15 PM EDT - 5 weeks ago

Arrowhead: Upcoming Plozasiran PDUFA Review Date And Subsequent Expansion In Place

Arrowhead and Novartis agree up to $2 billion deal for license to neuromuscular therapy

Sep 2, 2025, 8:13 AM EDT - 5 weeks ago

Arrowhead and Novartis agree up to $2 billion deal for license to neuromuscular therapy

NVS

Arrowhead Pharmaceuticals and Novartis Enter into a Global License and Collaboration Agreement

Sep 2, 2025, 7:30 AM EDT - 5 weeks ago

Arrowhead Pharmaceuticals and Novartis Enter into a Global License and Collaboration Agreement

Arrowhead Pharmaceuticals to Participate in Upcoming September 2025 Conferences

Aug 27, 2025, 7:30 AM EDT - 6 weeks ago

Arrowhead Pharmaceuticals to Participate in Upcoming September 2025 Conferences

Arrowhead Pharmaceuticals Redeems Approximately $50 Million of Arrowhead Stock and Will Receive Approximately $50 Million in Cash in Satisfaction of Milestone from Sarepta Therapeutics

Aug 13, 2025, 4:10 PM EDT - 2 months ago

Arrowhead Pharmaceuticals Redeems Approximately $50 Million of Arrowhead Stock and Will Receive Approximately $50 Million in Cash in Satisfaction of Milestone from Sarepta Therapeutics

Arrowhead Pharmaceuticals, Inc. (ARWR) Q3 2025 Earnings Call Transcript

Aug 8, 2025, 8:48 PM EDT - 2 months ago

Arrowhead Pharmaceuticals, Inc. (ARWR) Q3 2025 Earnings Call Transcript

Arrowhead Pharmaceuticals Reports Fiscal 2025 Third Quarter Results

Aug 7, 2025, 4:01 PM EDT - 2 months ago

Arrowhead Pharmaceuticals Reports Fiscal 2025 Third Quarter Results

Arrowhead Subsidiary Visirna Sells Rights to Hypertriglyceridemia Candidate Plozasiran in Greater China to Sanofi

Aug 1, 2025, 6:30 AM EDT - 2 months ago

Arrowhead Subsidiary Visirna Sells Rights to Hypertriglyceridemia Candidate Plozasiran in Greater China to Sanofi

Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics

Jul 28, 2025, 7:30 AM EDT - 2 months ago

Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics

SRPT

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Jul 24, 2025, 4:30 PM EDT - 2 months ago

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Arrowhead Pharmaceuticals Issues Statement on the Status of its Ongoing Agreement with Sarepta Therapeutics

Jul 23, 2025, 8:00 AM EDT - 2 months ago

Arrowhead Pharmaceuticals Issues Statement on the Status of its Ongoing Agreement with Sarepta Therapeutics

How The Negative Developments At Sarepta Therapeutics Impact Arrowhead Pharmaceuticals

Jul 22, 2025, 1:30 PM EDT - 2 months ago

How The Negative Developments At Sarepta Therapeutics Impact Arrowhead Pharmaceuticals

SRPT

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Third Quarter Results

Jul 21, 2025, 4:01 PM EDT - 2 months ago

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Third Quarter Results

Arrowhead Pharmaceuticals Initiates Phase 3 YOSEMITE Study of Investigational Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia

Jul 8, 2025, 7:30 AM EDT - 3 months ago

Arrowhead Pharmaceuticals Initiates Phase 3 YOSEMITE Study of Investigational Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia

Arrowhead Pharmaceuticals Completes Enrollment in SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 Studies of Plozasiran

Jun 23, 2025, 7:30 AM EDT - 3 months ago

Arrowhead Pharmaceuticals Completes Enrollment in SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 Studies of Plozasiran

Jim Cramer: Arrowhead Pharmaceuticals Doesn't 'Have The Horses'

Jun 4, 2025, 8:02 AM EDT - 4 months ago

Jim Cramer: Arrowhead Pharmaceuticals Doesn't 'Have The Horses'

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity

Jun 2, 2025, 7:30 AM EDT - 4 months ago

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity

Arrowhead Pharmaceuticals to Participate in June 2025 Investor Conferences

May 29, 2025, 7:30 AM EDT - 4 months ago

Arrowhead Pharmaceuticals to Participate in June 2025 Investor Conferences

Arrowhead Pharmaceuticals, Inc. (ARWR) Q2 2025 Earnings Call Transcript

May 12, 2025, 9:56 PM EDT - 5 months ago

Arrowhead Pharmaceuticals, Inc. (ARWR) Q2 2025 Earnings Call Transcript

Arrowhead Pharmaceuticals Reports Fiscal 2025 Second Quarter Results

May 12, 2025, 4:01 PM EDT - 5 months ago

Arrowhead Pharmaceuticals Reports Fiscal 2025 Second Quarter Results

Arrowhead Pharmaceuticals to Participate in May 2025 Investor Conferences

May 7, 2025, 7:30 AM EDT - 5 months ago

Arrowhead Pharmaceuticals to Participate in May 2025 Investor Conferences

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Second Quarter Results

Apr 30, 2025, 4:01 PM EDT - 5 months ago

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Second Quarter Results

Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial Officer

Apr 15, 2025, 4:00 PM EDT - 6 months ago

Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial Officer

Arrowhead Pharmaceuticals Is Finally Arriving

Mar 21, 2025, 5:56 PM EDT - 7 months ago

Arrowhead Pharmaceuticals Is Finally Arriving

Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy

Mar 10, 2025, 7:30 AM EDT - 7 months ago

Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy

Arrowhead Pharmaceuticals Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic Diseases

Mar 6, 2025, 8:45 AM EST - 7 months ago

Arrowhead Pharmaceuticals Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic Diseases

Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS)

Feb 28, 2025, 9:00 AM EST - 7 months ago

Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS)

Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ALK7 for Treatment of Obesity

Feb 25, 2025, 7:30 AM EST - 8 months ago

Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ALK7 for Treatment of Obesity

Arrowhead Pharmaceuticals: Progress During Adverse Market Conditions

Feb 19, 2025, 11:53 AM EST - 8 months ago

Arrowhead Pharmaceuticals: Progress During Adverse Market Conditions

Fat, not muscle: Drugmakers in race for next weight-loss breakthrough

Feb 19, 2025, 10:41 AM EST - 8 months ago

Fat, not muscle: Drugmakers in race for next weight-loss breakthrough

AZN BHVN KROS LLY NVO REGN SRRK

20 stocks of companies expected to put up numbers to back investors' new ‘growth mindset'

Feb 18, 2025, 10:20 AM EST - 8 months ago

20 stocks of companies expected to put up numbers to back investors' new ‘growth mindset'

AUB CRK CYTK EXE KRYS MARA MP

Arrowhead Pharmaceuticals, Inc. (ARWR) Q1 2025 Earnings Call Transcript

Feb 10, 2025, 9:35 PM EST - 8 months ago

Arrowhead Pharmaceuticals, Inc. (ARWR) Q1 2025 Earnings Call Transcript

Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results

Feb 10, 2025, 4:01 PM EST - 8 months ago

Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results

Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics

Feb 10, 2025, 8:30 AM EST - 8 months ago

Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics

SRPT

Guidewire Software Set to Join S&P MidCap 400; Arrowhead Pharmaceuticals to Join S&P SmallCap 600

Jan 22, 2025, 5:54 PM EST - 9 months ago

Guidewire Software Set to Join S&P MidCap 400; Arrowhead Pharmaceuticals to Join S&P SmallCap 600

GWRE

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 First Quarter Results

Jan 22, 2025, 4:00 PM EST - 9 months ago

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 First Quarter Results

Arrowhead Pharmaceuticals Announces Acceptance of New Drug Application by U.S. FDA of Plozasiran for the Treatment of Familial Chylomicronemia Syndrome

Jan 17, 2025, 4:30 PM EST - 9 months ago

Arrowhead Pharmaceuticals Announces Acceptance of New Drug Application by U.S. FDA of Plozasiran for the Treatment of Familial Chylomicronemia Syndrome

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity

Dec 23, 2024, 7:30 AM EST - 10 months ago

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity

Arrowhead Pharmaceuticals Presents Interim Clinical Data on ARO-CFB for the Treatment of Complement Mediated Diseases

Dec 11, 2024, 7:30 AM EST - 10 months ago

Arrowhead Pharmaceuticals Presents Interim Clinical Data on ARO-CFB for the Treatment of Complement Mediated Diseases

Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity

Dec 3, 2024, 7:30 AM EST - 11 months ago

Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity

Arrowhead Pharmaceuticals to Participate in Upcoming December 2024 Conferences

Dec 2, 2024, 7:30 AM EST - 11 months ago

Arrowhead Pharmaceuticals to Participate in Upcoming December 2024 Conferences

Arrowhead Pharmaceuticals, Inc. (ARWR) Q4 2024 Earnings Call Transcript

Nov 26, 2024, 11:08 PM EST - 11 months ago

Arrowhead Pharmaceuticals, Inc. (ARWR) Q4 2024 Earnings Call Transcript

LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 10 at 2:50 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $ARWR Current Share Price: $36.94 Contracts: $ARWR January 15, 2027 $40 Calls Scale in: $8.61- $10.53 Scale out: $13.40-$17.23 Can Easily Capture: 60% ROI Blended DTE: 463 Days | Join Elites here: https://liquidtheta.com/
0 · Reply
Steppinstone
Steppinstone Oct. 9 at 9:49 PM
$ARWR Interesting that an analyst covering IONS recently noted that Tryngolza would generate $ 1 billion in annual peak sales. That bodes very favorably for ARWR’s Plozasiran which is best in class and the superior drug. Been following ARWR for over a decade so it will be satisfying to see approval of its first drug in the coming weeks.
2 · Reply
skeezbag
skeezbag Oct. 9 at 7:04 PM
$ARWR don't go past 36.12 because that would make the picture painters gap not real!
0 · Reply
skeezbag
skeezbag Oct. 9 at 3:06 PM
$ARWR get ready to rage sheep
1 · Reply
Investor12341234
Investor12341234 Oct. 9 at 10:40 AM
$ARWR I wonder, how come the IV of NOV options are just average and not very high due to the FDA decision expected?
1 · Reply
Drashkawisha
Drashkawisha Oct. 9 at 5:20 AM
$ARWR The Final 3-Point Case for Arrowhead ($ARWR): FINANCIAL FORTRESS: The company holds over $900 Million in cash with a projected runway extending into 2028. This adheres perfectly to the "Zero Dilution Risk" rule, making it one of the safest setups in biotech. CLINICAL SUPERIORITY: The core drug (Plozasiran) is an RNAi therapeutic that demonstrated 80% triglyceride reduction and offers quarterly dosing for FCS, which is a significant competitive edge over monthly treatments. IMMINENT CATALYST: The PDUFA is confirmed for November 18, 2025. The current stock price (~$36.54) is a rare deep discount on the consensus analyst target (up to $80), making this a prime "Add-to-Position" opportunity.
1 · Reply
Food4Thought
Food4Thought Oct. 8 at 11:02 PM
$ARWR Someone who just reported on Oct 7th, loaded up very nicely. Nice increase of their position by 1,388% (over 380K shares valued over $13 million). You think they might have done some homework prior to this size of an increase?
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 8 at 6:18 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $ARWR Current Share Price: $36.85 Contracts: $ARWR January 15, 2027 $40 Calls Scale in: $8.67- $10.60 Scale out: $13.49-$17.34 Can Easily Capture: 60% ROI Blended DTE: 465 Days | Join Elites here: https://liquidtheta.com/
0 · Reply
skeezbag
skeezbag Oct. 8 at 1:53 PM
$ARWR almost time to rage against the GAP clowns
0 · Reply
TheSteveSmiths1
TheSteveSmiths1 Oct. 8 at 1:21 PM
$ARWR the numbers on this drug get insane quickly if you assume a 10k a year pricepoint. The true crown jewel. 1mill customer = $10 billion per year 5mill = $50 Billion per year 10mill = $100 billion per year
0 · Reply
Quantumup
Quantumup Oct. 8 at 11:48 AM
H.C. Wainwright reiterated $ARWR Buy-$80/said, With the November 18 PDUFA action date for plozasiran in familial chylomicronemia syndrome (FCS) approaching, we conducted several calls with Arrowhead management and key opinion leaders (KOLs) in the space. $IONS H.C. Wainwright added:
0 · Reply
G101SPM
G101SPM Oct. 8 at 10:25 AM
$ARWR $36.41 bid. CHANGE EXIT TO $50.00 https://stocktwits.com/G101SPM/message/614403674
0 · Reply
JarvisFlow
JarvisFlow Oct. 8 at 10:20 AM
HC Wainwright & Co. has adjusted their stance on Arrowhead Pharma ( $ARWR ), setting the rating to Buy with a target price of 80.
0 · Reply
Food4Thought
Food4Thought Oct. 8 at 7:15 AM
$ARWR ARWR about to get validation by Nov 18, 2025 for all their hard work over the years.
0 · Reply
Food4Thought
Food4Thought Oct. 8 at 6:56 AM
$ARWR This is the holy grail for ARWR. Make progress in these clinical trials, then lookout!
1 · Reply
HokieStock
HokieStock Oct. 8 at 1:27 AM
$ARWR looks like arrowhead has added Rage and MMP7 to core focus on the company website. Looking forward to hearing about both trials.
1 · Reply
13Tpro
13Tpro Oct. 7 at 2:25 PM
$ARWR Please don't publish any good news anymore... with Arwr it's always "sell on good news."
0 · Reply
Steppinstone
Steppinstone Oct. 7 at 12:25 PM
$ARWR The Dimer enters the clinic. This has the potential to be ARWR’s biggest drug. Mixed lipidemia population 15-20 mil. If the preclinical data holds up then this will be the best mixed lip drug in all of pharma.
0 · Reply
Steppinstone
Steppinstone Oct. 7 at 12:01 PM
$ARWR https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-files-cta-investigational-aro-dimer-pa
1 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 7 at 11:23 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $ARWR Current Share Price: $38.62 Contracts: $ARWR January 15, 2027 $40 Calls Scale in: $7.90- $9.66 Scale out: $12.29-$15.80 Can Easily Capture: 60% ROI Blended DTE: 466 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
ohkanby
ohkanby Oct. 7 at 11:02 AM
$ARWR this thing is on fire
0 · Reply
Steppinstone
Steppinstone Oct. 6 at 10:12 PM
$ARWR Moving closer each day to the approval of Plozasiran for FCS plus announcement of the label. Beginning to think that ARWR may not slow down and breath until it reaches a MC of $10 bil. given all of the upcoming catalysts.
2 · Reply